Gushengtang (HKG:2273) plans to repurchase its shares on the market for up to HK$200 million under the June 2024 granted repurchase mandate, a Friday Hong Kong bourse filing said.
The traditional Chinese medicine company was granted the repurchase mandate on June 18,, to repurchase up to a little over 24.5 million shares, representing 10% of the company's issued shares as of June 18.
The repurchase will be done from the filing date until the conclusion of the company's next annual general meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.